Home › Compare › GBLTF vs ABBV
GBLTF yields 19230.77% · ABBV yields 3.06%● Live data
📍 GBLTF pulled ahead of the other in Year 1
Combined, GBLTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GBLTF + ABBV for your $10,000?
GBLT Corp., through its subsidiary, German Battery Trading GmbH, manufactures and distributes mobile power products in Germany, the rest of the European Union, and internationally. It offers mobile lithium-based storage systems and solar panels, as well as a licenses home market for household storage systems under the Kodak brand; digital displays; LED lighting products under the Avide/ENTAC brand name; and face masks, disinfectants, insect repellants, and protective gloves, as well as electronic personal protection equipment products, such as fever thermometer, blood pressure oximeter, etc. under the Dr. Senst brand name. The company also produces and sells various types of batteries, such as lithium, alkaline, and heavy-duty batteries; and mobile energy products, such as batteries, storage systems, rechargeable batteries, and chargers under the AgfaPhoto brand name. In addition, it offers LED tubes and battery chemical systems; and medical products comprising hearing aid batteries and latex gloves under private labels. The company serves retail and commercial customers, as well as governments, public services, and industrial customers. It sells its products through supermarkets, department stores, drugstores, convenience stores, petrol stations, etc. The company is based in Toronto, Canada. GBLT Corp. is a subsidiary of SWT Beteiligungs AG.
Full GBLTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.